AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35751710 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping in diabetic pregnancies
Number of subjects: 261
Study 35751710 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping in normal pregnancies
Number of subjects: 261
Study 35751710 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping in normal pregnancies
Number of subjects: 261
Study 35751710 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping in diabetic pregnancies vs normal pregnancies
Number of subjects: 261
Study 32925256 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular block (SCB) with ropivacaine 0.5%
Number of subjects: 40
Study 32925256 — intervention group
Group type: COMPARATOR
Intervention: Retroclavicular block (RCB) with ropivacaine 0.5%
Number of subjects: 40
Study 34347626 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue self-management program (fatigue: take control)
Number of subjects: 218
Study 34347626 — intervention group
Group type: COMPARATOR
Intervention: Multiple sclerosis education program (multiple sclerosis: take control)
Number of subjects: 218
Study 33349200 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocuff-assisted colonoscopy (EC)
Number of subjects: 585
Study 33349200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-assisted colonoscopy (CAC)
Number of subjects: 585
Study 33349200 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 585
Study 33260697 — intervention group
Group type: EXPERIMENTAL
Intervention: W@W-App (intervention group; n = 90)
Number of subjects: 141
Study 33260697 — intervention group
Group type: COMPARATOR
Intervention: Active comparison group (A-CG; n = 51)
Number of subjects: 141
Study 34553652 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM with insulin therapy (Group 1)
Number of subjects: 319
Study 34553652 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM with diet (Group 2)
Number of subjects: 319
Study 34553652 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (Group 3)
Number of subjects: 319
Study 34553652 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM groups (Group 1 and Group 2)
Number of subjects: 319
Study 34553652 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal side SWE velocities
Number of subjects: 319
Study 34553652 — intervention group
Group type: EXPERIMENTAL
Intervention: Foetal side SWE velocities in GDM groups
Number of subjects: 319
Study 33849093 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support (WeChat group)
Number of subjects: 105
Study 33849093 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support (face-to-face group)
Number of subjects: 105
Study 33849093 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat group
Number of subjects: 105
Study 33849093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (WeChat and face-to-face)
Number of subjects: 105
Study 33849093 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study 36164033 — intervention group
Group type: EXPERIMENTAL
Intervention: A+AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine)
Number of subjects: 1334
Study 36164033 — intervention group
Group type: COMPARATOR
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 1334
Study 36164033 — intervention group
Group type: EXPERIMENTAL
Intervention: A+AVD
Number of subjects: 1334
Study 36164033 — intervention group
Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 1334
Study 33625251 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal association with CAD
Number of subjects: 840
Study 33625251 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact on lifespan potential
Number of subjects: 840
Study 33625251 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug targets identified
Number of subjects: 840
Study 33625251 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-cell expression analysis
Number of subjects: 840
Study 35804991 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin and Cyclophosphamide (EC)
Number of subjects: 275
Study 35804991 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel and Cyclophosphamide (TC)
Number of subjects: 275
Study 35637615 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Number of subjects: 40
Study 35637615 — intervention group
Group type: COMPARATOR
Intervention: Education/support (attention control)
Number of subjects: 40
Study 34842130 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level, multi-component obesity intervention
Number of subjects: 422
Study 34842130 — intervention group
Group type: COMPARATOR
Intervention: Comparison (Control)
Number of subjects: 422
Study 32863126 — intervention group
Group type: EXPERIMENTAL
Intervention: Subciliary approach
Number of subjects: 45
Study 32863126 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtarsal approach
Number of subjects: 45
Study 32863126 — intervention group
Group type: EXPERIMENTAL
Intervention: Transconjunctival approach
Number of subjects: 45
Study 36113495 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 80
Study 36113495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 34077482 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebos remotely
Number of subjects: 0
Study 34077482 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34694880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (20 mg)
Number of subjects: 8
Study 34694880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 34694880 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine (80/480 mg)
Number of subjects: 8
Study 33538777 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial reports of phase 3 RCTs
Number of subjects: 207
Study 33538777 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated reports of phase 3 RCTs
Number of subjects: 207
Study 32412683 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based paediatrician (IC)
Number of subjects: 296
Study 32412683 — intervention group
Group type: COMPARATOR
Intervention: Tertiary-hospital specialist allergy clinic (CC)
Number of subjects: 296
Study 32412683 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based model of care (IC)
Number of subjects: 296
Study 36073634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil (6 mg bolus followed by 6 mg/h infusion)
Number of subjects: 238
Study 36073634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 35297106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin with Ryutanshakanto
Number of subjects: 0
Study 35297106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin and Hachimijiogan
Number of subjects: 0
Study 35297106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35297106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin with Hachimijiogan
Number of subjects: 0
Study 35297106 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 0
Study 32555148 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Meal (MM) - 120 mL, 523 kJ (125 kcal) four times/day for 14 days
Number of subjects: 16
Study 32555148 — intervention group
Group type: COMPARATOR
Intervention: Electrolyte Solution (ES) - 50 kJ (12 kcal) four times/day for 14 days
Number of subjects: 16
Study 32555148 — intervention group
Group type: COMPARATOR
Intervention: Comparison of weight change between MM and ES
Number of subjects: 16
Study 35841104 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended cognitive behavioural therapy (12-week intervention consisting of five patient-therapist sessions and five to eight individualized web-based therapy modules with email support)
Number of subjects: 100
Study 35841104 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition (control group)
Number of subjects: 100
Study 35841104 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended cognitive behavioural therapy
Number of subjects: 100
Study 34051178 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 1010
Study 34051178 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1010
Study 34051178 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 1010
Study 34051178 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 1010
Study 32365097 — intervention group
Group type: EXPERIMENTAL
Intervention: Astodrimer 0.5% Gel
Number of subjects: 132
Study 32365097 — intervention group
Group type: EXPERIMENTAL
Intervention: Astodrimer 1% Gel
Number of subjects: 132
Study 32365097 — intervention group
Group type: EXPERIMENTAL
Intervention: Astodrimer 3% Gel
Number of subjects: 132
Study 32365097 — intervention group
Group type: COMPARATOR
Intervention: Placebo Gel
Number of subjects: 132
Study 36147650 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise (2 sessions of 90 min per week for 12 weeks)
Number of subjects: 39
Study 36147650 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (maintained usual daily routines for 12 weeks)
Number of subjects: 39
Study 33258213 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal High-flow Oxygen (NHF)
Number of subjects: 37
Study 33258213 — intervention group
Group type: COMPARATOR
Intervention: Conventional Oxygen Therapy (COT)
Number of subjects: 37
Study 33483868 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% octenidine mouthwash
Number of subjects: 201
Study 32032809 — intervention group
Group type: EXPERIMENTAL
Intervention: Parryscope technique
Number of subjects: 60
Study 32032809 — intervention group
Group type: COMPARATOR
Intervention: Flow technique
Number of subjects: 60
Study 32038465 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS before exercise on the treadmill
Number of subjects: 12
Study 32038465 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS before exercise on the treadmill
Number of subjects: 12
Study 35786002 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (exact dosage not specified)
Number of subjects: 0
Study 35786002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33835016 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (4 mg pridinol mesylate)
Number of subjects: 34
Study 33835016 — intervention group
Group type: COMPARATOR
Intervention: Reference product (4 mg pridinol mesylate)
Number of subjects: 34
Study 33835016 — intervention group
Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 34
Study 35098980 — intervention group
Group type: EXPERIMENTAL
Intervention: MTCC intervention
Number of subjects: 93
Study 35098980 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai-Chi Chuan intervention
Number of subjects: 93
Study 35098980 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 93
Study 35098980 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 93
Study 33285763 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based reablement group
Number of subjects: 26
Study 33285763 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 36076009 — intervention group
Group type: EXPERIMENTAL
Intervention: Atez/Bev (atezolizumab and bevacizumab)
Number of subjects: 426
Study 34479219 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental sensory feedback through vibrotactile stimulation
Number of subjects: 0
Study 34479219 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback policy (slow)
Number of subjects: 0
Study 34479219 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedforward policy (fast)
Number of subjects: 0
Study 36476534 — intervention group
Group type: EXPERIMENTAL
Intervention: Hex‐V
Number of subjects: 194
Study 36476534 — intervention group
Group type: COMPARATOR
Intervention: Hex‐IH
Number of subjects: 194
Study 33855195 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 12 weeks
Number of subjects: 72
Study 33855195 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CPAP therapy)
Number of subjects: 72
Study 32936713 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab monotherapy
Number of subjects: 275
Study 32936713 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab + chemotherapy
Number of subjects: 275
Study 36482326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin plus acetaminophen
Number of subjects: 66
Study 36482326 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus acetaminophen
Number of subjects: 66
Study 33796986 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS stimulation
Number of subjects: 52
Study 33796986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS stimulation
Number of subjects: 52
Study 33796986 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS stimulation
Number of subjects: 52
Study 35242882 — intervention group
Group type: EXPERIMENTAL
Intervention: C. lacerata (500 mg/capsule) for 12 weeks
Number of subjects: 90
Study 35242882 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 90
Study 34063306 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAL program (healthy empowered active lifestyles) intervention for 12 weeks
Number of subjects: 20
Study 33047653 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom intervention to promote glasses wearing (including classroom tracker, verbal reminders, and incentives)
Number of subjects: 44
Study 33047653 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom intervention to promote glasses wearing
Number of subjects: 44
Study 34111978 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-based CT radiomics features using Random Forest algorithm
Number of subjects: 81
Study 34111978 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-based CT radiomics features
Number of subjects: 81
Study 32666831 — intervention group
Group type: EXPERIMENTAL
Intervention: ticagrelor
Number of subjects: 0
Study 32666831 — intervention group
Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 0
Study 35896302 — intervention group
Group type: EXPERIMENTAL
Intervention: Family customised online FOCUS programme
Number of subjects: 142
Study 35896302 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (no elements of the FOCUS programme)
Number of subjects: 142
Study 34619441 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day Acceptance and Commitment Therapy (ACT) workshop
Number of subjects: 72
Study 34619441 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 33202928 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine Riding Simulator (ERS) program, 12 weeks, 3 times per week
Number of subjects: 80
Study 33202928 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 80
Study 35473594 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise targeting balance and lower limb strength (intervention group)
Number of subjects: 617
Study 35473594 — intervention group
Group type: COMPARATOR
Intervention: Exercise targeting upper limb strength (control group)
Number of subjects: 617
Study 33806051 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help app for Syrian refugees with PTSS
Number of subjects: 133
Study 35760595 — intervention group
Group type: EXPERIMENTAL
Intervention: Single thoracic SMT with a total peak force of 800N
Number of subjects: 19
Study 35760595 — intervention group
Group type: EXPERIMENTAL
Intervention: Single thoracic SMT with a total peak force of 400N
Number of subjects: 19
Study 35760595 — intervention group
Group type: COMPARATOR
Intervention: Control (preload only)
Number of subjects: 19
Study 33462716 — intervention group
Group type: EXPERIMENTAL
Intervention: DCIS score low-risk patients
Number of subjects: 4255
Study 33462716 — intervention group
Group type: EXPERIMENTAL
Intervention: DCIS score intermediate-risk patients
Number of subjects: 4255
Study 33462716 — intervention group
Group type: EXPERIMENTAL
Intervention: DCIS score high-risk patients
Number of subjects: 4255
Study 33462716 — intervention group
Group type: EXPERIMENTAL
Intervention: ER + disease with high-risk score
Number of subjects: 4255
Study 33462716 — intervention group
Group type: EXPERIMENTAL
Intervention: ER + disease with intermediate-risk score
Number of subjects: 4255
Study 33462716 — intervention group
Group type: EXPERIMENTAL
Intervention: ER - disease with low-risk score
Number of subjects: 4255
Study 33462716 — intervention group
Group type: EXPERIMENTAL
Intervention: ER - disease with intermediate-risk score
Number of subjects: 4255
Study 33462716 — intervention group
Group type: EXPERIMENTAL
Intervention: ER - disease with high-risk score
Number of subjects: 4255
Study 36394148 — intervention group
Group type: EXPERIMENTAL
Intervention: Anamorelin
Number of subjects: 0
Study 36394148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33556391 — intervention group
Group type: EXPERIMENTAL
Intervention: Large portion (200 g) consumed at home
Number of subjects: 119
Study 33556391 — intervention group
Group type: COMPARATOR
Intervention: Small portion (100 g) consumed at home
Number of subjects: 119
Study 33556391 — intervention group
Group type: EXPERIMENTAL
Intervention: Large portion (200 g) consumed in laboratory
Number of subjects: 119
Study 33556391 — intervention group
Group type: COMPARATOR
Intervention: Small portion (100 g) consumed in laboratory
Number of subjects: 119
Study 33556391 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard laboratory setting
Number of subjects: 119
Study 33556391 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-naturalistic laboratory setting
Number of subjects: 119
Study 35283003 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid repair (HR)
Number of subjects: 202
Study 35283003 — intervention group
Group type: COMPARATOR
Intervention: Open reconstruction (OR)
Number of subjects: 202
Study 32031879 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (goal to reduce fat intake to 20% of energy and increase vegetable, fruit, and grain intake)
Number of subjects: 48835
Study 32031879 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention
Number of subjects: 48835
Study 32031879 — intervention group
Group type: COMPARATOR
Intervention: Usual diet comparison group
Number of subjects: 48835
Study 33482315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammoxetine 2.5, 7.5, 15, 30, 45, 65, 100 mg (single-dose)
Number of subjects: 94
Study 33482315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammoxetine 15, 30, 45 mg (multiple-dose for 8 days)
Number of subjects: 94
Study 33482315 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single-dose and multiple-dose)
Number of subjects: 94
Study 34221032 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene regimen (OHR) including bioavailable stannous fluoride dentifrice, oscillating‐rotating electric toothbrush, cetylpyridinium chloride rinse, and floss
Number of subjects: 107
Study 34221032 — intervention group
Group type: COMPARATOR
Intervention: Usual care products (sodium fluoride dentifrice and manual toothbrush)
Number of subjects: 107
Study 32919092 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexxo-training (experimental group)
Number of subjects: 108
Study 32919092 — intervention group
Group type: COMPARATOR
Intervention: Active-control group
Number of subjects: 108
Study 32919092 — intervention group
Group type: COMPARATOR
Intervention: Passive-control group
Number of subjects: 108
Study 36817344 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 43
Study 36817344 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 43
Study 32172314 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage (group A)
Number of subjects: 80
Study 32172314 — intervention group
Group type: COMPARATOR
Intervention: No drainage (group B)
Number of subjects: 80
Study 34391247 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga module (5 days per week for 6 weeks)
Number of subjects: 82
Study 34391247 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 82
Study 32819949 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN) with stretching protocol
Number of subjects: 102
Study 32819949 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Needle Electrolysis (PNE) with stretching protocol
Number of subjects: 102
Study 34990712 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCC1 inhibitor probenecid
Number of subjects: 14
Study 34990712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 35870435 — intervention group
Group type: EXPERIMENTAL
Intervention: Teach‐to‐Goal (TTG) education
Number of subjects: 394
Study 35870435 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Teach‐to‐Goal (V‐TTG) education
Number of subjects: 394
Study 35870435 — intervention group
Group type: COMPARATOR
Intervention: Brief Intervention (BI) education
Number of subjects: 394
Study 35870435 — intervention group
Group type: EXPERIMENTAL
Intervention: High health literacy
Number of subjects: 394
Study 35870435 — intervention group
Group type: COMPARATOR
Intervention: Low health literacy
Number of subjects: 394
Study 33244045 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive corrective exercise program (CCEP) for 8 weeks
Number of subjects: 24
Study 33244045 — intervention group
Group type: EXPERIMENTAL
Intervention: CCEP
Number of subjects: 24
Study 33244045 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal daily activities)
Number of subjects: 24
Study 35555662 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine Nitrate (CN: 5 g/day + 0.675 g/day of maltodextrin)
Number of subjects: 12
Study 35555662 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF: 400 mg/day + 5 g/day of maltodextrin)
Number of subjects: 12
Study 35555662 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine Nitrate + Caffeine (CN+CAF: 5 g/day of creatine nitrate + 400 mg/day of caffeine)
Number of subjects: 12
Study 35555662 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL: 5.4 g/day of maltodextrin)
Number of subjects: 12